Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

Chari, Ajai; T. Vogl, Dan; Gavriatopoulou, Maria; K. Nooka, Ajay; J. Yee, Andrew; Ann Huff, Carol; Moreau, Philippe; Dingli, David; E. Cole, Craig; Lonial, Sagar; Α. Dimopoulos, Meletios; Keith Stewart, A.; Richter, Joshua; Vij, Ravi; A. Tuchman, Sascha; S. Raab, Marc; Weisel, Katja; Delforge, Michel; F. Cornell, Robert; Kaminetzky, David; E. Hoffman, James; J. Costa, Luciano; L. Parker, Terri; Levy, Moshe; Schreder, Martin; Meuleman, Nathalie; Frenzel, Laurent; Mohty, Mohamad; Choquet, Sylvain; J. Schiller, Gary; L. Comenzo, Raymond; Engelhardt, Monika; Illmer, Thomas; Vlummens, Philip; Doyen, Chantal; Façon, Thierry; Karlin, Lionel; Perrot, Aurore; Podar, Klaus; Kauffman, Michael; Shacham, Sharon; Li, Lingling; Tang, Shijie; Picklesimer, Carla; Saint‐Martin, Jean‐Richard; Crochiere, Marsha; Chang, Hua; Parekh, Samir; Landesman, Yosef; J. Shah, Jatin; G. Richardson, Paul; Jagannath, Sundar

doi:10.1056/nejmoa1903455

Public

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

Published in New England Journal of Medicine • Aug 21, 2019

Authors:

Ajai Chari

Dan T. Vogl

Maria Gavriatopoulou

Abstract

BACKGROUND: Selinexor, a selective inhibitor of nuclear export compound that blocks exportin 1 (XPO1) and forces nuclear accumulation and activation of tumor suppressor proteins, inhibits nuclear factor κB, and reduces oncoprotein messenger RNA translation, is a potential novel treatment for myeloma...

Subject

Daratumumab

Pomalidomide

Carfilzomib

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!